Alexandra Tuuk
Medical · Cartersville, GANPI 1306102421
Payments from drug & device makers
Across 123 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$981
- AbbVie$319
- Incyte Corporation$292
- Astellas Pharma US Inc$276
- Janssen Scientific Affairs, LLC$169
- Pharmacyclics LLC, An Abbvie Company$152
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,419100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 32 | $981 |
| AbbVie | 8 | $319 |
| Incyte Corporation | 10 | $292 |
| Astellas Pharma US Inc | 11 | $276 |
| Janssen Scientific Affairs, LLC | 7 | $169 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $152 |
| Johnson & Johnson | 7 | $140 |
| E.r. Squibb & Sons, L.L.C. | 1 | $126 |
| Pfizer | 4 | $123 |
| Sanofi-aventis U.S. LLC | 5 | $118 |
| Legend Biotech USA Inc. | 4 | $85 |
| Seagen Inc. | 5 | $75 |
| Sanofi | 1 | $71 |
| Gilead | 2 | $56 |
| ADC Therapeutics America, Inc. | 2 | $41 |
| Amgen | 2 | $39 |
| Karyopharm Therapeutics Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Genmab U.S., Inc. | 1 | $32 |
| Novartis | 1 | $31 |
| Merck | 1 | $31 |
| Jazz Pharmaceuticals Inc. | 1 | $26 |
| Coherus Oncology, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $21 |
| Rigel Pharmaceuticals, Inc. | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $19 |
| Morphosys, US Inc. | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Blueprint Medicines Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,419 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 17 | $299,291 |
| VemlidyTenofovir Alafenamide | 12 | $15,299 |
| Acyclovir | 24 | $606 |
| Penicillin V Potassium | 24 | $161 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $27 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sanofi-aventis U.S. LLCRezurock | $118 | $299,29117 claims |
| GileadVemlidy | $56 | $15,29912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.
Other medical in Cartersville
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.